Press Release: INOVIO Announces the Appointment of Michael Cordera As Executive Vice President & General Counsel
Press Release: INOVIO Announces the Appointment of Michael Cordera As Executive Vice President & General Counsel
Press Release: INOVIO Announces the Appointment of Michael Cordera As Executive Vice President & General Counsel
新闻稿：Inovio宣布任命Michael Cordera为执行副总裁兼总法律顾问
INOVIO Announces the Appointment of Michael Cordera As Executive Vice President & General Counsel
Inovio公司宣布任命迈克尔·科德拉为执行副总裁兼总法律顾问
PR Newswire
美通社
PLYMOUTH MEETING, Pa., March 15, 2021
宾夕法尼亚州普利茅斯会议，2021年3月15日
PLYMOUTH MEETING, Pa., March 15, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the appointment of Michael Cordera as Executive Vice President and General Counsel. Mr. Cordera will serve on the company's executive leadership team and will report to INOVIO's President and Chief Executive Officer, Dr. J. Joseph Kim. In this role, he will be responsible for the company's legal team and strategy.
亚洲网宾夕法尼亚州普利茅斯会议2021年3月15日电专注于将精确设计的DNA药物推向市场的生物技术公司Inovio(纳斯达克市场代码：INO)今天宣布任命迈克尔·科德拉(Michael Cordera)为执行副总裁兼总法律顾问。科德拉先生将在公司的执行领导团队任职，并向Inovio公司总裁兼首席执行官J·约瑟夫·金博士汇报工作。在这个职位上，他将负责公司的法律团队和战略。
Dr. J. Joseph Kim, INOVIO's President and CEO, said, "Michael is a seasoned legal executive with deep life sciences experience both in the US and abroad. His expertise surrounding commercial operations and global business development come at a key time for our organization. He will be a valuable leader as INOVIO executes on its plans to develop and commercialize DNA medicines to treat infectious diseases, cancer, and HPV-associated diseases."
Inovio总裁兼首席执行官J.Joseph Kim博士说：“Michael是一位经验丰富的法律高管，在美国和国外都有丰富的生命科学经验。他在商业运营和全球业务发展方面的专业知识正值我们组织的关键时刻。随着Inovio执行其开发和商业化治疗传染病、癌症和HPV相关疾病的DNA药物的计划，他将成为一个有价值的领导者。”
Mr. Cordera joins INOVIO from Eagle Pharmaceuticals, where he served as General Counsel and Chief Compliance Officer. Before Eagle, Michael held various legal positions of increasing responsibility at Warner Chilcot and inVentiv (now Syneos) Health where he was responsible for legal affairs in North America, Europe, and Asia. Mr. Cordera began his legal career as an Associate at Sherman & Sterling, LLP. He holds a J.D. from the Rutgers School of Law and an undergraduate degree from the American University of Paris.
科德拉先生从Eagle制药公司加盟Inovio公司，在那里他担任总法律顾问和首席合规官。在Eagle之前，Michael在Warner Chilcot和InVentiv(现在的Syneos)Health担任各种责任日益增加的法律职位，负责北美、欧洲和亚洲的法律事务。科德拉先生作为Sherman&Sterling，LLP的一名律师开始了他的法律职业生涯。他拥有罗格斯法学院(Rutgers School Of Law)的法学博士学位和巴黎美国大学(American University Of Paris)的本科学位。
About INOVIO's DNA Medicines Platform
关于Inovio的DNA药物平台
INOVIO has 15 DNA medicine clinical programs currently in development focused on HPV-associated diseases, cancer, and infectious diseases, including coronaviruses associated with COVID-19 and MERS, for which programs are being developed with funding support from the U.S. Department of Defense and the Coalition for Epidemic Preparedness Innovations (CEPI). DNA medicines are composed of optimized DNA plasmids, which are small circles of double-stranded DNA that are synthesized or reorganized by a computer sequencing technology and designed to produce a specific immune response in the body.
英诺威公司目前有15个脱氧核糖核酸药物临床项目正在开发中，重点研究人乳头瘤病毒相关疾病、癌症和传染病，包括与新冠肺炎和中东呼吸综合征相关的冠状病毒，这些项目正在美国国防部和防疫创新联盟的资金支持下开发。DNA药物是由优化的DNA质粒组成的，这些质粒是由双链DNA组成的小圈，通过计算机测序技术合成或重组，旨在在体内产生特定的免疫反应。
INOVIO's DNA medicines deliver optimized plasmids directly into cells intramuscularly or intradermally using INOVIO's proprietary hand-held smart device called CELLECTRA(R) . The CELLECTRA(R) device uses a brief electrical pulse to reversibly open small pores in the cell to allow the plasmids to enter, overcoming a key limitation of other DNA and other nucleic acid approaches, such as mRNA. Once inside the cell, the DNA plasmids enable the cell to produce the targeted antigen. The antigen is processed naturally in the cell and triggers the desired T cell and antibody-mediated immune responses. Administration with the CELLECTRA(R) device is designed to ensure that the DNA medicine is efficiently delivered directly into the body's cells, where it can go to work to drive an immune response. INOVIO's DNA medicines do not interfere with or change in any way an individual's own DNA. The advantages of INOVIO's DNA medicine platform are how fast DNA medicines can be designed and manufactured; the stability of the products, which do not require freezing in storage and transport; and the robust immune response, safety profile, and tolerability that have been observed in clinical trials.
Inovio公司的DNA药物使用Inovio公司专有的名为CELLECTRA(R)的手持智能设备，通过肌肉内或皮内直接将优化后的质粒输送到细胞内。CELLECTRA(R)设备使用短暂的电脉冲可逆地打开细胞中的小孔，使质粒得以进入，从而克服了其他DNA和其他核酸方法(如mRNA)的一个关键限制。一旦进入细胞，DNA质粒就能使细胞产生目标抗原。抗原在细胞中自然处理，并触发所需的T细胞和抗体介导的免疫反应。使用CELLECTRA(注册商标)设备进行管理的目的是确保DNA药物有效地直接输送到人体细胞，在那里它可以工作以驱动免疫反应。Inovio的DNA药物不会以任何方式干扰或改变个人自身的DNA。Inovio的DNA药物平台的优势是设计和制造DNA药物的速度很快；产品的稳定性，不需要在储存和运输过程中冷冻；以及在临床试验中观察到的强大的免疫反应、安全性和耐受性。
With more than 3,000 patients receiving INOVIO investigational DNA medicines in more than 7,000 applications across a range of clinical trials, INOVIO has a strong track record of rapidly generating DNA medicine candidates with potential to meet urgent global health needs.
在一系列临床试验的7000多种应用中，有3000多名患者接受了Inovio的研究DNA药物治疗，Inovio在快速产生有潜力满足全球紧迫健康需求的DNA药物候选药物方面有着良好的记录。
About INOVIO
关于Inovio
INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with HPV. INOVIO is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. INOVIO's lead immunotherapy candidate, VGX-3100, currently in Phase 3 trials for precancerous cervical dysplasia, cleared high-risk HPV-16 and/or HPV-18 in a Phase 2b clinical trial. High-risk HPV is responsible for 70% of cervical cancer, 91% of anal cancer, and 69% of vulvar cancer. Also in development are programs targeting HPV-related cancers and a rare HPV-related disease, recurrent respiratory papillomatosis (RRP); non-HPV-related cancers glioblastoma multiforme (GBM) and prostate cancer; as well as infectious disease DNA vaccine development programs in coronaviruses associated with COVID-19 diseases and MERS, Lassa fever, Ebola, and HIV. Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA)/Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND)/Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Richter-Helm BioLogics, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. INOVIO also is a proud recipient of 2020 Women on Boards "W" designation recognizing companies with more than 20% women on their board of directors. For more information, visit www.inovio.com.
Inovio是一家生物技术公司，专注于将精确设计的DNA药物迅速推向市场，以治疗和保护人们免受传染病、癌症和与HPV相关的疾病的侵袭。Inovio是第一家也是唯一一家在临床上证明DNA药物可以通过专有智能设备直接进入人体细胞，以产生强大和可耐受的免疫反应的公司。Inovio公司的主要免疫治疗候选药物VGX-3100目前正处于癌前宫颈发育不良的3期试验，在2b期临床试验中清除了高危HPV-16和/或HPV-18。高危HPV导致70%的宫颈癌、91%的肛门癌和69%的外阴癌。同时还在开发针对人乳头瘤病毒相关癌症和一种罕见的人乳头瘤病毒相关疾病(复发性呼吸道乳头状瘤病)、非人乳头瘤病毒相关癌症、多形性胶质母细胞瘤和前列腺癌的项目，以及针对与新冠肺炎疾病和中东呼吸综合征、拉沙热、埃博拉病毒和艾滋病相关的冠状病毒的传染病DNA疫苗开发项目。合作伙伴和合作者包括Adaccine、ApolloBio公司、阿斯利康公司、比尔和梅林达·盖茨基金会、防疫创新联盟(CEPI)、国防高级研究计划局(DARPA)/化学、生物、辐射和核防御联合项目执行办公室(JPEO-CBRND)/国防部(DoD)、艾滋病毒疫苗试验网络、国际疫苗研究所(IVI)、卡内卡Eurogentec、医学CBRN防御联盟(Plebline生命科学，Regeneron，Richter-Helm生物制品，Thermo Fisher Science，宾夕法尼亚大学，沃尔特·里德陆军研究所, 和维斯塔尔研究所。Inovio还自豪地获得了2020年度女性董事会“W”称号，表彰董事会中女性比例超过20%的公司。欲了解更多信息，请访问www.inovio.com。
CONTACTS:
联系人：
Media: Jeff Richardson, 267-440-4211, jrichardson@inovio.com
媒体：杰夫·理查森(Jeff Richardson)电话：267-440-4211电子邮件：jrichardson@inovio.com
Investors: Ben Matone, 484-362-0076, ben.matone@inovio.com
投资者：本·马通(Ben Matone)电话：484-362-0076电子邮件：ben.matone@inovio.com
This press release contains certain forward-looking statements relating to our business, including our plans to develop and commercialize DNA medicines. There can be no assurance that any product candidate in our pipeline will be successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law.
本新闻稿包含一些与我们的业务相关的前瞻性陈述，包括我们开发和商业化DNA药物的计划。不能保证我们正在筹备中的任何候选产品将被成功开发、制造或商业化，不能保证临床试验的最终结果将支持上市产品所需的监管批准，也不能保证本文提供的任何前瞻性信息将被证明是准确的。前瞻性陈述仅在本新闻稿发布之日发表，除非法律要求，否则我们不承担更新或修改这些陈述的义务。
View original content:http://www.prnewswire.com/news-releases/inovio-announces-the-appointment-of-michael-cordera-as-executive-vice-president--general-counsel-301247078.html
查看原始content:http://www.prnewswire.com/news-releases/inovio-announces-the-appointment-of-michael-cordera-as-executive-vice-president--general-counsel-301247078.html
SOURCE INOVIO Pharmaceuticals, Inc.
来源：Inovio制药公司
/Web site: www.inovio.com
网址：www.inovio.com
(END) Dow Jones Newswires
(完)道琼通讯社
March 15, 2021 08:00 ET (12:00 GMT)
2021年3月15日东部时间08：00(格林尼治标准时间12：00)
译文内容由第三方软件翻译。